source
- Vertex Q1 revenue slightly below forecasts as key drug sales miss estimates, but Alyftrek revenue surgesVertex Pharmaceuticals reported first‑quarter revenue of about $3 billion, falling just short of Wall Street expectations. The modest miss left the stock largely unchanged on the day of the release…
- Pfizer CEO Albert Bourla rules out any transformative merger plansOn the May 5, 2026 earnings call, Pfizer chief Albert Bourla was asked whether the company was considering a transformative merger in the near or medium term. Bourla answered that Pfizer has no pl…